All News

Evernorth has capped antiobesity drug monthly co-pays at $200 in a move to improve access and affordability amid new drug pricing initiatives.

A causal link between chronic spontaneous urticaria and gut microbiota, with metabolic pathways potentially acting as mediators, offer new avenues for research and clinical understanding.

Once-daily roflumilast provides skin clearance and rapid itch relief with no limitation on duration of use.

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

Veterans primarily receiving care through the Department of Veterans Affairs (VA) similarly used dental and vision services under Medicare Advantage (MA) and traditional Medicare, challenging the justification for full MA capitated payments based on supplemental benefits.

Even a 2% decline in lung function predicted poor outcomes for patients with idiopathic pulmonary fibrosis (IPF) in a new study.

The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is transforming the role of pharmacists in enhancing patient care.

As concerns grow nationally about the mental health of young people, a new study provides insight into ongoing debates about social media’s role.

Emma Achola-Kothari, PhD, explains that younger Medicare beneficiaries without supplemental coverage face high costs, while dual-eligible beneficiaries in Medicare Advantage plans struggle with provider access.

New global analysis calls for urgent, targeted interventions as aging populations face rising rates of skin cancer.

Minimally invasive glaucoma surgery offers alternatives for patients looking for methods of treating glaucoma without affecting quality of life.

SCAN Group takes ownership of an integrated care delivery organization, to expand its impact on the lives of vulnerable seniors.

The executive order that President Donald Trump signed to lower drug prices could come under legal challenges by the drug industry.

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of life in patients with eosinophilic chronic obstructive pulmonary disease (COPD).

Nerandomilast significantly slowed lung function decline and reduced mortality in patients with progressive pulmonary fibrosis (PPF), with consistent efficacy regardless of background antifibrotic therapy.

Ali Khawar, former Department of Labor official, explains the original intent of a federal rule to reinforce the Mental Health Parity and Addiction Equity Act could be under threat as the Trump administration walks back enforcement.

While artificial intelligence (AI) is transforming community oncology, Nini Wu, MD, of Navista, emphasizes that success depends on patient access and infrastructure.

The ALPHA3 trial is exploring cemacabtagene ansegedleucel's (cema-cel) potential to enhance outcomes in patients who have relapsed/refractory large B-cell lymphoma, particularly those positive for minimal residual disease.

Researchers are working to redefine diagnosis and treatment with data-driven tools aimed at identifying patients earlier and guiding precision care.

Following President Donald Trump's most favored nation executive order, HHS and CMS have released the target price for pharmaceutical manufacturers to meet.

HHS announces it is taking steps to implement President Trump’s Executive Order on prescription drug pricing. Keep up with the latest moves made in health policy under President Donald Trump's second administration. This timeline will be updated as orders and policy progress.

Sleep disorders and mental health complications were more common in adolescents or young adults who had HIV across the globe.

In an era that FDA Commissioner Marty Makary, MD, MPH, calls an "epidemic of distrust" toward health institutions, previously contained disease rates are rapidly rising, and vaccination rates are proceeding in the opposite direction.

Proposed Medicaid cuts risk increasing health disparities, leaving millions uninsured and limiting access to essential care for vulnerable populations.

The latest results from the phase 3 FIBRONEER-IPF trial showed consistent benefit of nerandomilast in patients with idiopathic pulmonary fibrosis (IPF) whether or not they were receiving background antifibrotic therapy.

Research presented at the American Thoracic Society (ATS) 2025 International Conference used FDA-approved tools to see how sleep can impact other parts of recovery for patients in the intensive care unit (ICU).

Childhood cancer survivors face heightened risks of chronic kidney disease and hypertension, necessitating urgent updates to monitoring guidelines for their long-term health.

The FDA previously approved Jivi in 2018 to treat adults aged 12 years and older with hemophilia A.

Over 500,000 US patients hospitalized with nonsevere COVID-19 saw no clinically significant benefit and potential harm associated with routine early antibiotic treatment, supporting antibiotic stewardship to limit unnecessary use.

The FDA cleared marketing for the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.